Search

everythinglearnresearchcommunity

for

Search:↓

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Canakinumab's effect on COVID-19 outcomes is unclear.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

Etanercept, a psoriasis treatment, caused hair loss in a patient.

The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Switching to a twice-weekly betamethasone treatment led to full hair regrowth in alopecia areata without side effects.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

A patient with complete hair loss regrew all her hair using tofacitinib.

Azathioprine can cause severe blood issues and hair loss, needing careful monitoring and possible discontinuation.

The treatment was effective for lupus nephritis with manageable side effects.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.